MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Lapatinib ditosylate monohydrate

CAS No. : 388082-78-8

MCE 站：Lapatinib ditosylate monohydrate

产品活性：Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) 是一种 ErbB-2 和 EGFR 酪氨酸激酶结构域的有效抑制剂，对纯化的 EGFR 和 ErbB-2 的 IC₅₀ 值分别为 10.2 和 9.8 nM。

研究领域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK  |  Autophagy  |  Apoptosis

作用靶点：EGFR  |  Autophagy  |  Ferroptosis

In Vitro: Lapatinib (GW2016; 0.03-10 M; 6 hours; BT474 ａnd HN5 cells) treatment inhibits receptor autophosphorylation of EGFR ａnd ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was inhibited by GW2016 in a dose-dependent manner.
Lapatinib (GW2016; 72 hours; HN5, A-43, BT474, N87, ａnd CaLu-3 cells) treatment has a selective inhibition of the proliferation of human tumor cell lines.
Lapatinib (GW2016; 1-10 M; 72 hours; HN5 cells) treatment results in induces G1 arrest.

In Vivo: Lapatinib (GW2016; 30-100 mg/kg; oral administration; twice daily; for 21 days; CD-1 nude female mice) treatment inhibits tumor xenograft growth of the HN5 cells in a dose-responsive manner at 30 ａnd 100 mg/kg, with complete inhibition of tumor growth at the higher dose.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Ferroptosis Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Hepatitis C Virus Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-prostate Cancer Compound Library  |  Ferrostatin-1  |  Erastin  |  Cisplatin  |  RSL3  |  Acetylcysteine  |  Cycloheximide  |  Sorafenib  |  Necrostatin-1  |  SP600125  |  ML385  |  Osimertinib  |  Gefitinib  |  Trastuzumab  |  Rosiglitazone  |  Erlotinib  |  Liproxstatin-1  |  Cetuximab  |  Curcumin  |  Afatinib  |  Roxadustat  |  AG490  |  Hemin  |  Simvastatin  |  TBHQ  |  Lapatinib  |  U-73122  |  Lovastatin  |  Sulfasalazine  |  L-Glutathione reduced  |  Trolox

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。